Drug Eluting Balloons Market Size, Share, Trends, Growth Outlook

Drug Eluting Balloons Market is estimated to increase at a growth rate of 8.5% CAGR over the forecast period from 2024 to 2030.

The global Drug Eluting Balloons Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Coronary, Peripheral), By Technology (FreePac, TransPac, EnduraCoat, Others), By End-User (Hospitals, Ambulatory Surgical Centers, Others).

An Introduction to Drug Eluting Balloons Market in 2024

The Drug Eluting Balloons Market includes medical devices used in interventional cardiology and peripheral vascular procedures to deliver therapeutic agents directly to arterial walls while dilating and opening narrowed or blocked blood vessels. Drug-eluting balloons (DEBs) combine balloon angioplasty with drug delivery, releasing anti-restenotic drugs to prevent vessel re-narrowing and improve long-term outcomes in patients with coronary artery disease, peripheral artery disease, and other vascular conditions. With advancements in drug-eluting technologies, the drug-eluting balloons market continues to evolve, offering minimally invasive treatment options for cardiovascular and peripheral vascular diseases.

Drug Eluting Balloons Market Competitive Landscape

The global Drug Eluting Balloons Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Drug Eluting Balloons Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Drug Eluting Balloons Industry include- B. Braun Melsungen AG, Becton, Dickson and Company, Biotronik, Boston Scientific Corp, Cook Group Inc, Koninklijke Philips NV, Medtronic Plc, SurModics Inc, Terumo Corp.

Drug Eluting Balloons (DEBs) Market Trend: Shift Towards Minimally Invasive Cardiovascular Interventions

One Market Trend in the drug-eluting balloons (DEBs) market is the shift towards minimally invasive cardiovascular interventions. DEBs offer an alternative to traditional stent-based treatments for coronary artery disease, providing targeted drug delivery directly to the site of vessel stenosis while avoiding the need for permanent implantation of metal scaffolds. As patients and healthcare providers increasingly prioritize less invasive treatment options that minimize procedural risks, recovery time, and long-term complications, DEBs are gaining traction as a viable therapeutic option for patients with coronary artery disease. The trend towards minimally invasive interventions is driving the adoption of DEBs in clinical practice, fueling innovation in balloon technologies, drug formulations, and procedural techniques to optimize patient outcomes and reduce the burden of cardiovascular disease.

Drug Eluting Balloons Market Driver: Rising Prevalence of Cardiovascular Diseases and Demand for Effective Treatment Solutions

The driver behind the demand for drug-eluting balloons (DEBs) is the rising prevalence of cardiovascular diseases and the growing demand for effective treatment solutions. Cardiovascular diseases, including coronary artery disease, peripheral artery disease, and restenosis following angioplasty, are leading causes of morbidity and mortality worldwide, imposing a significant burden on healthcare systems and patient quality of life. As the global burden of cardiovascular diseases continues to escalate due to aging populations, sedentary lifestyles, and the increasing prevalence of risk factors such as obesity, diabetes, and hypertension, there is a pressing need for innovative treatment options that improve clinical outcomes, reduce repeat interventions, and enhance patient satisfaction. DEBs offer a targeted approach to inhibit neointimal hyperplasia and reduce the risk of restenosis following angioplasty procedures, addressing a critical unmet need in the management of coronary and peripheral arterial diseases. The demand for DEBs is driven by the desire to improve long-term patency rates, minimize the need for repeat revascularization procedures, and optimize patient outcomes in the management of cardiovascular diseases.

Drug Eluting Balloons Market Opportunity: Expansion of Indications and Application of DEBs in Emerging Cardiovascular Interventions

An opportunity exists for the expansion of indications and application of drug-eluting balloons (DEBs) in emerging cardiovascular interventions beyond traditional coronary artery disease. While DEBs have demonstrated efficacy in reducing restenosis rates following balloon angioplasty in coronary arteries, there is potential to explore their utility in other vascular territories and disease conditions, such as peripheral artery disease, venous diseases, and structural heart interventions. By expanding the scope of DEB applications, manufacturers can address a broader range of clinical needs, tap into new market segments, and differentiate their product offerings in the competitive cardiovascular device landscape. Additionally, exploring innovative drug formulations, combination therapies, and drug-eluting coatings tailored to specific disease pathologies and anatomical locations may enhance the therapeutic efficacy and safety profile of DEBs, opening up opportunities for personalized treatment approaches and precision medicine in cardiovascular care. By leveraging advancements in balloon technologies, drug delivery platforms, and clinical evidence generation, stakeholders can unlock the full potential of DEBs in revolutionizing the treatment of cardiovascular diseases and improving patient outcomes across diverse patient populations and clinical settings.

Market Share Analysis: Drug Eluting Balloons (DEBs) in Peripheral Applications is the fastest growing segment in the Drug Eluting Balloons industry

DEBs in peripheral applications represent the fastest growing segment among the mentioned categories. This growth can be attributed to several factors. Firstly, the rising prevalence of peripheral arterial disease (PAD) has increased the demand for effective treatment options. DEBs offer a minimally invasive solution for treating PAD by delivering drugs directly to the affected area, reducing the risk of restenosis. Additionally, technological advancements in DEB designs, such as the development of coatings like EnduraCoat, have improved the efficacy and durability of these devices, further driving adoption rates. Moreover, the shift towards outpatient settings, including ambulatory surgical centers, for peripheral interventions has contributed to the expansion of this market segment. As healthcare systems increasingly prioritize cost-effective and less invasive treatment options, DEBs in peripheral applications are poised for continued rapid growth.

Drug Eluting Balloons Market Segmentation

By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Drug Eluting Balloons Companies

B. Braun Melsungen AG
Becton, Dickson and Company
Biotronik
Boston Scientific Corp
Cook Group Inc
Koninklijke Philips NV
Medtronic Plc
SurModics Inc
Terumo Corp
* List not Exhaustive

Reasons to Buy the Drug Eluting Balloons Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Drug Eluting Balloons Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Drug Eluting Balloons Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Drug Eluting Balloons Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Drug Eluting Balloons Market Size Outlook, $ Million, 2021 to 2030
3.2 Drug Eluting Balloons Market Outlook by Type, $ Million, 2021 to 2030
3.3 Drug Eluting Balloons Market Outlook by Product, $ Million, 2021 to 2030
3.4 Drug Eluting Balloons Market Outlook by Application, $ Million, 2021 to 2030
3.5 Drug Eluting Balloons Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Drug Eluting Balloons Industry
4.2 Key Market Trends in Drug Eluting Balloons Industry
4.3 Potential Opportunities in Drug Eluting Balloons Industry
4.4 Key Challenges in Drug Eluting Balloons Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Drug Eluting Balloons Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Drug Eluting Balloons Market Outlook by Segments
7.1 Drug Eluting Balloons Market Outlook by Segments, $ Million, 2021- 2030
By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others
8 North America Drug Eluting Balloons Market Analysis and Outlook To 2030
8.1 Introduction to North America Drug Eluting Balloons Markets in 2024
8.2 North America Drug Eluting Balloons Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Drug Eluting Balloons Market size Outlook by Segments, 2021-2030
By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others
9 Europe Drug Eluting Balloons Market Analysis and Outlook To 2030
9.1 Introduction to Europe Drug Eluting Balloons Markets in 2024
9.2 Europe Drug Eluting Balloons Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Drug Eluting Balloons Market Size Outlook by Segments, 2021-2030
By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others
10 Asia Pacific Drug Eluting Balloons Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Drug Eluting Balloons Markets in 2024
10.2 Asia Pacific Drug Eluting Balloons Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Drug Eluting Balloons Market size Outlook by Segments, 2021-2030
By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others
11 South America Drug Eluting Balloons Market Analysis and Outlook To 2030
11.1 Introduction to South America Drug Eluting Balloons Markets in 2024
11.2 South America Drug Eluting Balloons Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Drug Eluting Balloons Market size Outlook by Segments, 2021-2030
By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others
12 Middle East and Africa Drug Eluting Balloons Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Drug Eluting Balloons Markets in 2024
12.2 Middle East and Africa Drug Eluting Balloons Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Drug Eluting Balloons Market size Outlook by Segments, 2021-2030
By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
B. Braun Melsungen AG
Becton, Dickson and Company
Biotronik
Boston Scientific Corp
Cook Group Inc
Koninklijke Philips NV
Medtronic Plc
SurModics Inc
Terumo Corp
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Coronary
Peripheral
By Technology
FreePac
TransPac
EnduraCoat
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Others